Immunotech Laboratories, Inc. and Immunotech Laboratories, BG announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd., located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company's HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa. With the establishment of an African operation, Immunotech hopes to fulfill the Company's vision of bringing a therapy based on the patented Inactivated Pepsin Fraction (IPF) protein developed by Immunotech for infectious diseases such as HIV/AIDS, Hepatitis C and a new potential initiative, the Ebola virus.

In parts of Africa, approved experimental treatments are permitted, and with the Ebola outbreak, Immunotech expects that it can market its treatment for infectious diseases through the Company's new agreement with Uldic. ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is promising in combination with protease inhibitors in the treatment of the HIV/AIDS virus. IPF is a platform technology that can be used to facilitate a broad range of applications.

It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use. IPF has not shown itself to be subject to viral resistance, and it is cost effective.